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GYN GEC – ESTRO Recommendations for MR Image Based 
Brachytherapy. 
Results: Dosimetric outcome: The mean + SD HR-CTV was 45.2 +15.8 
cc and 42.5 + 19.5 cc for RD and PD experience respectively. The 
mean + SD point A dose was 73.4+4.5 Gy in RD experience Vs 93 + 24.8 
Gy with PD experience. Similarly,the mean + SD D90 doses were 70.9 + 
10.6 Gy for RD Vs 87.2 +4.4 Gy for PD data. For OAR's, the mean + SD 
ICRU rectal and bladder points were 63.5 + 8.1 and 80.4 + 34.4 Gy 
respectively. The D2cc for rectum, bladder and sigmoid for RD data 
were 57.8 + 7.7 Gy, 93.4 +24.6 Gy and 74.6 + 19.6 Gy while it was 64 + 
5.5 Gy, 74.8 +7.1 Gy and 65.2 + 5.4 Gy respectively for PD set.  
Clinical Outcome: For RD experience, with a median follow-up of 24 
months, 3 patients had local failure, 1 had right external iliac nodal 
failure, and 1 left supraclavicular nodal failure whereas for PD 
experience with a median follow-up of 16 months, 3 had local 
recurrence,1 nodal, 4: loco-regional + distant and 3 patients had 
distant failures. All the local recurrences in both the RD and PD 
experience were HR-CTV infield relapses. In RD experience, 1 patient 
had Grade ¾ procto-sigmoiditis (Sigmoid 2cc : 140 Gy ) whereas so far 
no patient has been reported with significant late toxicity in PD 
experience. 
Conclusions: There is an overall significant improvement in 
therapeutic ratio in favour of PD experience. With the HR-CTV 
volumes being the same, the target volume doses are higher, doses to 
sigmoid and bladder are lower. The clinical outcome looks promising 
in terms of local control rates, however, longer follow-up is required 
to assess late sequelae. 
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Purpose/Objective: Three dimensional image-guided brachytherapy 
allows the assessment of the dose to organs at risk with Dose Volume 
Histograms (DVHs). The purpose of this study was to find a correlation 
between the DVHs and in-vivo dosimetry measurements for the 
bladder and rectum. 
Materials and Methods: During the period from 2009 to 2011, a total 
of 17 cervix carcinoma patients were treated with High Dose Rate 
brachytherapy (Ir-192). After the implantation of the catheter and 
previous to the treatment, the patients were CT scanned generating a 
total of 28 CT datasets. In-vivo dosimetry was performed 2 to 3 times 
on each patient using Thermo Luminescence Dosimeters of LiF (TLD-
100). The TLD rods were inserted in plastic tubes and separated with 
wires to facilitate their location on the CT scan. The tubes were 
introduced in urethral and rectal catheters inside the patient. The 
TLDs were calibrated every treatment day using the same Ir-192 
source that was used for the treatment. Protocols of annealing and 
read-out were followed to reduce uncertainties in dose measurements 
around brachytherapy sources. A retrospective study of these patients 
was performed after the acquisition of the brachytherapy dose 
planning system, OncentraR Brachy v4.0. The 28 CT datasets were 
imported in the dose planning system, the bladder and rectum 
delineated, a dose plan reproducing the received treatment was 
generated and the DVHs calculated. The minimum dose to 5cc, 2cc, 
1cc and 0.1cc tissue receiving the highest dose (D5cc, D2cc, D1cc and 
D0.1cc) was recorded and correlated to the maximum and average dose 
measured with the TLDs.  
Results: Statistically significant correlation (p<0.001) was found 
between the bladder volumetric doses (D5cc, D2cc, D1cc and D0.1cc) and 
the measured maximum and average dose. The correlation 
coefficients were 0.83, 0.85, 0.87 and 0.87 respectively for the 
maximum dose and 0.84, 0.86, 0.86 and 0.85 respectively for the 
average dose. For the rectal data no statistically significant 
correlation was found (p<0.3). The correlation coefficients were 0.39, 
0.39, 0.38, 0.34 respectively for the maximum dose and 0.15, 0.15, 
0.14, 0.13 respectively for the average dose. 
Conclusions: The significant correlation between the volumetric 
bladder doses and the measurements indicate that in-vivo dosimetry is 
an important method of quality assurance and could be used as a 
complement to the 3D image-guided brachytherapy. The lack of 
correlation in the rectal data might be due to the length of the rectal 
catheter that reached the sigmoid area when it was fully inserted. 
Therefore the rectal measurements correspond to the sigmoid dose 
and not to the rectal dose. As a result of this study we started to use 
a shorter catheter to assure that the TLDs are located at the rectum.  
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Purpose/Objective: HDR brachytherapy is widely used for tumor 
treatment. The main disadvantage is that using Ir-192 requires heavily 
shielded treatment room with an expensive remote control room. The 
main purpose of this work is to develop a HDR brachytherapy source 
that can be used in every regular hospital operation room without the 
need of very expensive treatment and control rooms.We have found 
Tm-170 to be a suitable isotope for that purpose. We have 
manufactured many Tm-170 seeds and we present here the results of 
animal experiments and dosimetry of those Tm-170 sources.  
Materials and Methods: Thulium-170 (Tm-170) is a radioactive isotope 
of half-life128 days, emitting photons in the range of 7-84 keV (~11% 
of the radiation emitted) and two beta rays of energy E max = 880 keV 
24%, and E max = 970 keV 76%. Many Tm-170 seeds for the LDR 
treatment were made and one source for the HDR treatment. The LDR 
seeds were made of thulium rectangles of dimensions: 4 x 0.6 x 0.2 
mm or cylindrical of 0.6 mm diameter, 4 mm long. The thulium was 
inserted into titanium sealed tube of 0.8 mm od, 0.7 mm id and 7 mm 
long. LDR experiments were done with seed activity in the range 0.5-
2.5 mCi. The HDR source was made of thulium cylinder 0.6 diameter 5 
mm long inside a titanium tube, all in a stainless steel tube of 1.2 mm 
od, 1.0 mm id. It was activated to about 5 Ci. Dosimetry of the Tm 
170 sources was done using a number of different methods and was 
calculated with Monte Carlo codes. TLD and film dosimetry were done 
in a Perspex phantom, in the range 4 – 30 mm from the source center. 
Measurements with LUDLUM NaI(Tl) dosimeter were done in air. 80 
BALB/C mice carrying KHJJ tumor were used in the LDR experiments 
and 12 Lewis rats carrying CNS1 Rat brain tumor were used in the HDR 
experiments 
Results: Survival of the treated animals is as follows: 60% of the 
treated mice were fully cured compared to none of the control, 75% 
of the rats were fully cured compared to none of the control. 
Dosimetry yielded the following results: The average of the many dose 
measurements of both the LDR seeds and the HDR source at 1 cm from 
the source (seed) in a Perspex phantom was 236 cGy/h Ci. That is 
about 20 times smaller than the dose from Ir-192 source at 1 cm. 
When theTm-170 seed is wrapped with 0.1 mm thick gold foil, to 
remove the beta radiation, the photon dose at 1 cm is reduced by a 
factor of 2.  
Conclusions: The survival of the treated animals is very encouraging, 
in particular for the HDR experiments. As for the dosimetry, Tm-170 
yields a lower photon dose at 1 cm from the source than Ir-192, 
however, if the beta radiation is acceptable, than the dose in the 
range up to 3 mm from the source is higher for Tm-170 than for Ir-
192. To avoid hot spots near the source the beta can be partly remove 
by wrapping the source with a thin gold coat. The Tm-170 activity 
should be higher and the seeds can be implanted at distances smaller 
than 1 cm. The benefit of avoiding heavy shielding worth the effort. 
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Purpose/Objective: Robust and relevant quality control (QC) is 
essential to ensure accuracy and safety in radiotherapy. QC in HDR 
brachytherapy has not kept pace with clinical modernisation e.g. 
volume-based prescriptions and patient-specific inverse-optimisation. 
New QC standards are required to confirm dose distribution accuracy 
and avoid errors. Typical QC is currently limited to straight catheters, 
point doses and well chambers. A 'state of the art' practical 
implementation of advanced multichannel film dosimetry is presented 
to verify delivered dose distributions around treatment applicators 
and sources. 3 cases are presented; a cervix ring applicator, a 
shielded vaginal cylinder, and an isolated source catheter. The 
application of gamma assessment criteria in brachytherapy is 
discussed. 
Materials and Methods: A film-array water phantom was used to 
accurately position Gafchromic EBT3 film, cut to 12 x 12 cm. 
Multichannel film dosimetry separating dose-dependent and dose-
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independent components was used (FimQAPro). Dose-maps were 
compared to treatment plans using isodoses and gamma. Absolute film 
dose values were used with no re-normalisation of any data. Isolated 
source doses were compared to TG-43 source model values. The value 
and sensitivity of gamma for brachytherapy applications was assessed 
by multivariate analysis of area/position and calculation parameters. 
Eckert & Ziegler Bebig GmbH HDR multiSource treatment unit, with 
Co-60 source, and HDRplus treatment planning system (TPS) were 
used throughout. 
Results: Figure 1 shows dose maps from 2 films positioned adjacent to 
and bisecting the cervix applicator intrauterine (IU) channel, overlaid 
on TPS isodoses. Agreement in isodoses, 75 cGy to 2000 cGy, is 
generally within 1.0 mm. A comparison of the 2 symmetric films 
confirms sufficient reproducibility. Table 1 provides example gamma 
results for the cervix and shielded vaginal applicators. The passing 
rate in brachytherapy is sensitive to the defined interest region, in the 
cervix example ranging from 95% at typical HR-CTV to 100% at a 
bladder position, for 3% (local) / 2 mm criteria, evaluated over 9 cm2 
regions. The full-region, 144 cm2, passing rate was ~ 98%. 
The validity of the TG-43 general source model for individual supplied 
HDR sources was successfully verified. Gamma passing rates > 95% at 
3% (local) / 2 mm between 5 mm and 50 mm from the source. 
 
 
 
 
 
 
  
Conclusions: There is an absence of clinically-relevant QC for modern 
brachytherapy. We have presented a practical, robust method of 
advanced film dosimetry of treatment applicators, which is more 
closely aligned to clinical treatments than current QC. Planned and 
measured isodoses agreed closely, with high gamma passing rates. 
Film dosimetry is advocated to confirm validity of the general TG-43 
model for individual supplied sources. The use and sensitivity of 
gamma for brachytherapy must be carefully considered; we propose 
separate calculations in a number of clinically relevant regions. 
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Purpose/Objective: In permanent seed implant prostate 
brachytherapy the actual dose delivered to the patient may be less 
than that calculated by TG43-U1 due to inter-seed attenuation (ISA) 
and differences between prostate tissue composition and water. In 
this study the ISA effect is assessed using Monte Carlo (MC) simulation 
of clinical prostate treatment plans. 
Materials and Methods: Simulations of ultrasound based pre-plans and 
CT based post-plans were performed for 30 patients treated with 6711 
seeds, the mean activity used was 0.44U. MC simulation results were 
compared to TG43-U1 using DVH parameters for the prostate, urethra, 
rectum and the volume enclosed by the 100% isodose. Use of gamma 
index values to compare MC simulation results and TG43-U1 was 
investigated. Areas of the prostate where ISA caused dose to drop 
below 100% of prescription dose were analysed. Sector analysis of ISA 
effects was performed dividing the prostate into apex, mid-gland and 
base segments, with each segment divided into anterior, posterior, 
left and right quadrants. 
Results: For CT post-plans, the mean ISA effect was to reduce 
prostate D90 by 4.2Gy (3%), prostate V100 by 0.5cc (1.4%), urethra 
D10 by 11.3Gy (4.4%), rectal D2cc by 5.5Gy (4.6%) and the 100% 
isodose volume by 2.3cc. For ultrasound pre-plans the mean ISA effect 
was smaller, reducing prostate D90 by 2.2% and the 100% isodose 
volume by 1.5cc. For distance to agreement 2mm and dose difference 
3% the number of points in the prostate with gamma <=1 was 95.3% 
for CT based post-plans and 97.8% for US based pre-plans. The number 
of points with gamma <=1 correlated strongly with ISA effect on DVH 
parameters (p<0.01). Sector analysis showed that in CT post-plans the 
majority of points where ISA causes prostate dose to fall below 100% 
are near the prostate base however this is not true for ultrasound pre-
plans as these have more uniform coverage and seed spacing. 
Conclusions: ISA causes the delivered dose in prostate seed implant 
brachytherapy to be lower than the dose calculated by TG43-U1. 
Because of differences in seed positions between pre-plan and post-
plan, the effect of ISA on the post-plan could not necessarily be 
predicted from the pre-plan. For this group of patients ISA had most 
impact at the prostate base, an area which is often underdosed even 
excluded any effects of ISA.  
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Purpose/Objective: It is well-known that tissue heterogeneities and 
calcifications have significant influence on low energy brachytherapy 
such as prostate permanent I-125 implants. The aim of this work is to 
study the application of a simplified analytic algorithm that could be 
compatible with commercial Treatment Planning System (TPS) based 
on TG-43. The algorithm, based on the classic equivalent path length 
method, has been tested with Monte Carlo (MC) computations using 
Penelope2009. 
Materials and Methods: The analytical model scales the distance from 
the seed to the calculation point according to the electronic density 
of the medium relative to water. Then the dose is obtained from TG-
43 consensus data stored on a TPS but with the radial dose function 
obtained for the scaled distance keeping the anisotropy function 
unaltered. A voxelized phantom obtained from real cases has been 
used. This case was selected as a benchmark because the patient 
presented a significant proportion of calcifications inside the prostate. 
After this step a comparison between MC and the algorithm was 
performed.  
Results: The results given by the algorithm show a remarkable 
agreement with the complete Monte Carlo simulations taking into 
account the calcifications in the aforementioned real case. Several 
other realistic geometries and compositions of the calcification have 
been checked successfully. In the figure below two different imaging 
planes can be observed (black arrows in the insets). Blue lines stands 
for TG-43 based results, green lines for the algorithm, and red ones 
for MC simulations. More overdose rate times the distance squared 
and divided by air-kerma strength is given. 
 
